115 related articles for article (PubMed ID: 18381195)
1. Development and optimization of a binding assay for histone deacetylase 4 using surface plasmon resonance.
Mattu M; Di Giovine P; Steinkuhler C; De Francesco R; Altamura S; Cecchetti O; Carfì A; Barbato G
Anal Biochem; 2008 Jun; 377(2):267-9. PubMed ID: 18381195
[TBL] [Abstract][Full Text] [Related]
2. Optimization of a series of potent and selective ketone histone deacetylase inhibitors.
Pescatore G; Kinzel O; Attenni B; Cecchetti O; Fiore F; Fonsi M; Rowley M; Schultz-Fademrecht C; Serafini S; Steinkühler C; Jones P
Bioorg Med Chem Lett; 2008 Oct; 18(20):5528-32. PubMed ID: 18809328
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitor assay based on fluorescence resonance energy transfer.
Riester D; Hildmann C; Schwienhorst A; Meyer-Almes FJ
Anal Biochem; 2007 Mar; 362(1):136-41. PubMed ID: 17250798
[TBL] [Abstract][Full Text] [Related]
4. A spectrophotometric assay for histone deacetylase 8.
Fatkins DG; Zheng W
Anal Biochem; 2008 Jan; 372(1):82-8. PubMed ID: 17920554
[TBL] [Abstract][Full Text] [Related]
5. A series of novel, potent, and selective histone deacetylase inhibitors.
Jones P; Altamura S; Chakravarty PK; Cecchetti O; De Francesco R; Gallinari P; Ingenito R; Meinke PT; Petrocchi A; Rowley M; Scarpelli R; Serafini S; Steinkühler C
Bioorg Med Chem Lett; 2006 Dec; 16(23):5948-52. PubMed ID: 16987657
[TBL] [Abstract][Full Text] [Related]
6. A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.
Jones P; Altamura S; De Francesco R; Paz OG; Kinzel O; Mesiti G; Monteagudo E; Pescatore G; Rowley M; Verdirame M; Steinkühler C
J Med Chem; 2008 Apr; 51(8):2350-3. PubMed ID: 18370373
[TBL] [Abstract][Full Text] [Related]
7. Comparative molecular dynamics simulations of histone deacetylase-like protein: binding modes and free energy analysis to hydroxamic acid inhibitors.
Yan C; Xiu Z; Li X; Li S; Hao C; Teng H
Proteins; 2008 Oct; 73(1):134-49. PubMed ID: 18398905
[TBL] [Abstract][Full Text] [Related]
8. Novel histone deacetylase inhibitors: cyclic tetrapeptide with trifluoromethyl and pentafluoroethyl ketones.
Jose B; Oniki Y; Kato T; Nishino N; Sumida Y; Yoshida M
Bioorg Med Chem Lett; 2004 Nov; 14(21):5343-6. PubMed ID: 15454224
[TBL] [Abstract][Full Text] [Related]
9. Non-isotopic dual parameter competition assay suitable for high-throughput screening of histone deacetylases.
Riester D; Hildmann C; Haus P; Galetovic A; Schober A; Schwienhorst A; Meyer-Almes FJ
Bioorg Med Chem Lett; 2009 Jul; 19(13):3651-6. PubMed ID: 19457659
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders.
Kazantsev AG; Thompson LM
Nat Rev Drug Discov; 2008 Oct; 7(10):854-68. PubMed ID: 18827828
[TBL] [Abstract][Full Text] [Related]
11. Eosin Y as an internal standard for a plate reader-based quantitation of a histone deacetylase substrate.
Heltweg B; Jung M
Arch Pharm (Weinheim); 2002 Jun; 335(6):296-300. PubMed ID: 12210773
[TBL] [Abstract][Full Text] [Related]
12. Identification of novel, selective, and stable inhibitors of class II histone deacetylases. Validation studies of the inhibition of the enzymatic activity of HDAC4 by small molecules as a novel approach for cancer therapy.
Ontoria JM; Altamura S; Di Marco A; Ferrigno F; Laufer R; Muraglia E; Palumbi MC; Rowley M; Scarpelli R; Schultz-Fademrecht C; Serafini S; Steinkühler C; Jones P
J Med Chem; 2009 Nov; 52(21):6782-9. PubMed ID: 19888759
[TBL] [Abstract][Full Text] [Related]
13. Identification of selective class II histone deacetylase inhibitors using a novel dual-parameter binding assay based on fluorescence anisotropy and lifetime.
Haus P; Korbus M; Schröder M; Meyer-Almes FJ
J Biomol Screen; 2011 Dec; 16(10):1206-16. PubMed ID: 22027638
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and modeling of new benzofuranone histone deacetylase inhibitors that stimulate tumor suppressor gene expression.
Charrier C; Clarhaut J; Gesson JP; Estiu G; Wiest O; Roche J; Bertrand P
J Med Chem; 2009 May; 52(9):3112-5. PubMed ID: 19385600
[TBL] [Abstract][Full Text] [Related]
15. Molecular basis of the anti-cancer effects of histone deacetylase inhibitors.
Epping MT; Bernards R
Int J Biochem Cell Biol; 2009 Jan; 41(1):16-20. PubMed ID: 18765293
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.
Attenni B; Ontoria JM; Cruz JC; Rowley M; Schultz-Fademrecht C; Steinkühler C; Jones P
Bioorg Med Chem Lett; 2009 Jun; 19(11):3081-4. PubMed ID: 19410459
[TBL] [Abstract][Full Text] [Related]
17. Development of a scintillation proximity assay for histone deacetylase using a biotinylated peptide derived from histone-H4.
Nare B; Allocco JJ; Kuningas R; Galuska S; Myers RW; Bednarek MA; Schmatz DM
Anal Biochem; 1999 Feb; 267(2):390-6. PubMed ID: 10036146
[TBL] [Abstract][Full Text] [Related]
18. First non-radioactive assay for in vitro screening of histone deacetylase inhibitors.
Hoffmann K; Brosch G; Loidl P; Jung M
Pharmazie; 2000 Aug; 55(8):601-6. PubMed ID: 10989838
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy.
Piekarz RL; Sackett DL; Bates SE
Cancer J; 2007; 13(1):30-9. PubMed ID: 17464244
[TBL] [Abstract][Full Text] [Related]
20. New pyrrole-based histone deacetylase inhibitors: binding mode, enzyme- and cell-based investigations.
Mai A; Valente S; Nebbioso A; Simeoni S; Ragno R; Massa S; Brosch G; De Bellis F; Manzo F; Altucci L
Int J Biochem Cell Biol; 2009 Jan; 41(1):235-47. PubMed ID: 18834955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
